ClinicalTrials.gov
public full text
Public Domain
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of TP-04 in Participants With Papulopustular Rosacea#832241
- Treatment of Moderate to Severe Plaque Psoriasis#849449
- The Impact of Age on Botulinum Toxin Potency in Facial Rhytides Treatment#892345
- Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus#913180
- Efficacy of the PARI LC Sprint Sp Nebulizer for Acute Asthma Attack in Hospitalized Children Less Than 36 Months of Age#1057893
Record · ID 871754
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive